Online inquiry

IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11918MR)

This product GTTS-WQ11918MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets GUCY2C gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_004963.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2984
UniProt ID P25092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11918MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15465MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA U3-1287
GTTS-WQ4094MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BI-204
GTTS-WQ15029MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ10169MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LC1004-002
GTTS-WQ958MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-323
GTTS-WQ6255MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CR-6261
GTTS-WQ1685MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACZ885
GTTS-WQ2244MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ALX-0171
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW